[PDF][PDF] The phenobarbital response enhancer module in the human bilirubin UDP‐glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR
J Sugatani, H Kojima, A Ueda, S Kakizaki… - …, 2001 - Wiley Online Library
The UDP‐glucuronosyltransferase, UGT1A1, is the critical enzyme responsible for detoxification
of the potentially neurotoxic bilirubin by conjugating it with glucuronic acid. For decades, …
of the potentially neurotoxic bilirubin by conjugating it with glucuronic acid. For decades, …
Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia
…, T Machida, H Takagi, M Mori, S Kakizaki… - Biochemical and …, 2002 - Elsevier
The UDP-glucuronosyltransferase UGT1A1 plays a critical role in the detoxification of potentially
neurotoxic bilirubin by conjugating it with glucuronic acid. We identified a polymorphism …
neurotoxic bilirubin by conjugating it with glucuronic acid. We identified a polymorphism …
Estrogen Activation of the Nuclear Orphan Receptor CAR (Constitutive Active Receptor) in Induction of the Mouse Cyp2b10 Gene
T Kawamoto, S Kakizaki, K Yoshinari… - Molecular …, 2000 - academic.oup.com
The nuclear orphan receptor CAR (constitutively active receptor or constitutive androstane
receptor) can be activated in response to xenochemical exposure, such as activation by …
receptor) can be activated in response to xenochemical exposure, such as activation by …
Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis
D Takizawa, S Kakizaki, N Sohara, K Sato… - Digestive diseases and …, 2007 - Springer
Hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is associated with
a poor prognosis. New therapeutic modalities, such as continuous hepatic arterial infusion …
a poor prognosis. New therapeutic modalities, such as continuous hepatic arterial infusion …
[HTML][HTML] Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population
…, C Ogawa, T Nishimura, T Hatanaka, S Kakizaki… - European Journal of …, 2023 - Elsevier
Background and aims Atezolizumab plus bevacizumab and lenvatinib have not been
compared in a randomised controlled trial. We conducted a retrospective multi-centre study to …
compared in a randomised controlled trial. We conducted a retrospective multi-centre study to …
A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and …
…, H Hashizume, N Horiguchi, S Kakizaki… - Official journal of the …, 2015 - journals.lww.com
OBJECTIVES: The aim of this study was to assess the long-term prognosis, efficacy, and
safety of combination therapy using ursodeoxycholic acid (UDCA) and bezafibrate (BF) for …
safety of combination therapy using ursodeoxycholic acid (UDCA) and bezafibrate (BF) for …
Functional gastrointestinal disorders in adolescents and quality of school life
T Sagawa, S Okamura, S Kakizaki… - Journal of …, 2013 - Wiley Online Library
Background and Aim The prevalence of functional gastrointestinal disorders ( FGID ) in
adolescents and their relationship to quality of school life ( QOSL ) are not fully understood. This …
adolescents and their relationship to quality of school life ( QOSL ) are not fully understood. This …
Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with child‐Pugh class a or B liver function in …
…, T Nishimura, T Hatanaka, S Kakizaki… - Hepatology …, 2022 - Wiley Online Library
Background/Aim Atezolizumab plus bevacizumab (Atez/Bev) treatment is recommended for
unresechepatocellular carcinoma (u‐HCC) patients classified as Child‐Pugh A (CP‐A). This …
unresechepatocellular carcinoma (u‐HCC) patients classified as Child‐Pugh A (CP‐A). This …
Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus …
T Hatanaka, S Kakizaki, A Hiraoka, T Tada… - Hepatology …, 2022 - Springer
Aim This study aimed to investigate the utility of C-reactive protein (CRP) and alpha-fetoprotein
(AFP) in immunotherapy (CRAFITY) score in hepatocellular carcinoma (HCC) patients …
(AFP) in immunotherapy (CRAFITY) score in hepatocellular carcinoma (HCC) patients …
[HTML][HTML] SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
…, D Kohno, T Sasaki, K Takeuchi, S Kakizaki… - Molecular …, 2019 - Elsevier
Objectives It is controversial whether sodium glucose transporter (SGLT) 2 inhibitors increase
glucagon secretion via direct inhibition of SGLT2 in pancreatic α cells. The role of SGLT1 …
glucagon secretion via direct inhibition of SGLT2 in pancreatic α cells. The role of SGLT1 …